Anti-Infectives Have Blockbuster Future Despite Personalized Medicine
Executive Summary
Anti-infectives have the potential to remain top-selling products in the future even as personalized medicine curtails the number of therapies achieving blockbuster status, Lehman Brothers Vice Chairman Frederic Frank said
You may also be interested in...
Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal
Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline
Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal
Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline
Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says
Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis